REFERENCES
1. Cines DB, McKenzie SE, Siegel DL. Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003;25 Suppl 1:S52-S56.
2. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 2008;4(6):317-327.
3. Piek CJ, Junius G, Dekker A, et al. Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors
in 149 dogs. J Vet Intern Med 2008;22(2):366-373.
4. Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 1999;35(5):384-391.
5. Weinkle TK, Center SA, Randolph JF, et al. Evaluation of prognostic factors, survival rates, and treatment protocols for
immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc 2005;226(11):1869-1880.
6. Goggs R, Boag AK, Chan DL. Concurrent immune-mediated haemolytic anaemia and severe thrombocytopenia in 21 dogs. Vet Rec 2008;163(11):323-327.
7. Palmeiro BS, Morris DO, Goldschmidt MH, et al. Cutaneous reactive histiocytosis in dogs: a retrospective evaluation of 32
cases. Vet Dermatol 2007;18(5):332-340.
8. Vargo CL, Taylor SM, Haines DM. Immune mediated neutropenia and thrombocytopenia in 3 giant schnauzers. Can Vet J 2007;48(11):1159-1163.
9. Olivry T, Bergvall KE, Atlee BA. Prolonged remission after immunosuppressive therapy in six dogs with pemphigus foliaceus.
Vet Dermatol 2004;15(4):245-252.
10. Rosenkrantz WS. Pemphigus: current therapy. Vet Dermatol 2004;15(2):90-98.
|
Featuring Information from:
